Serum Levels of Urokinase Plasminogen Activator Receptor (suPAR) Discriminate Moderate Uncontrolled from Severe Asthma.

ABSTRACT:

Introduction

The most clinically useful concept in asthma is based on the intensity of treatment required to achieve good asthma control. Biomarkers to guide therapy are needed.

Aims

To investigate the role of circulating levels of soluble urokinase plasminogen activator receptor suPAR as a marker for asthma severity.

Methods

We recruited patients evaluated at the Asthma Clinic, University of Thessaly, Greece. Asthma severity and control were defined according to the GINA strategy and Asthma Contro Test (ACT). Anthropometrics, spirometry, fractional exhaled nitric oxide (FeNO), suPAR, blood cell count, c-reactive protein (CRP), and analyses of kidney and liver function were obtained. Patients with a history of inflammatory, infectious, or malignant disease or other lu

SUBMITTER: Kotsiou OS 

PROVIDER: S-EPMC9693242 | biostudies-literature | 2022 Oct

REPOSITORIES: biostudies-literature